Abstract: The present invention relates to a DoxA protein mutant having an amino acid sequence set forth in SEQ ID NO: 16, and coding gene thereof. The protein mutant or the coding gene thereof can be used for producing epirubicin. The present invention further relates to a Streptomyces capable of efficiently expressing epirubicin, which is constructed by replacing the dnmV gene of a starting Streptomyces in situ with the avrE gene and mutating the doxA gene of the starting Streptomyces into a gene encoding the protein set forth in SEQ ID NO: 16. The fermentation broth of this Streptomyces has an epirubicin potency of up to 102.0 ?g/ml.

Abstract: The present invention relates to a DoxA protein mutant having an amino acid sequence set forth in SEQ ID No. 16, and coding gene thereof. The protein mutant or the coding gene thereof can be used for producing epirubicin. The present invention further relates to a Streptomyces capable of efficiently expressing epirubicin, which is constructed by replacing the dnmV gene of a starting Streptomyces in situ with the avrE gene and mutating the doxA gene of the starting Streptomyces into a gene encoding the protein set forth in SEQ ID No. 16. The fermentation broth of this Streptomyces has an epirubicin potency of up to 102.0 ?g/ml.

Abstract: The invention provides a construction method of spinosad heterologous expression strain, a spinosad heterologous expression strain obtained by the method and use thereof in preparing spinosad. The method utilizes a plurality of homologous recombination to replace the erythromycin synthetic gene cluster of Saccharopolyspora erythraea with the spinosad synthetic gene cluster and the rhamnose synthetic gene cluster, such that the Saccharopolyspora erythraea produces spinosad.

Abstract: The present invention relates to a recombinant microorganism expressing avermectin or analogs thereof and construction method thereof, and also relates to a method of producing avermectin or analogs thereof using the recombinant microorganism, and avermectin or analogs thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogs thereof as insecticides. Using the recombinant microorganism of the present invention to produce avermectin or analogs thereof has numerous advantages, for example comprising at least one of the following: good stability, high yield, simple process, environmentally friendly, and greatly saving of production costs.

Abstract: A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.

Abstract: A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.

Abstract: A bacterial strain of Actinoplanes sp. and and the use thereof. The bacterial strain is named Actinoplanes sp. HS-16-20, whose preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 7294. The bacterial strain can be used to generate Fidaxomicin or analogs thereof or compositions containing Fidaxomicin, such as by aerobically fermenting the strain in nutrient medium containing assimilable carbon and/or nitrogen sources. Fidaxomicin has an inhibitory effect on various gram positive bacteria pathogens, and in particular, on Clostridium difficile.

Abstract: The invention provides a construction method of spinosad heterologous expression strain, a spinosad heterologous expression strain obtained by the method and use thereof in preparing spinosad. The method utilizes a plurality of homologous recombination to replace the erythromycin synthetic gene cluster of Saccharopolyspora erythraea with the spinosad synthetic gene cluster and the rhamnose synthetic gene cluster, such that the Saccharopolyspora erythraea produces spinosad.

Abstract: The present invention relates to a recombinant microorganism expressing avermectin or analogues thereof and construction method thereof, and also relates to a method of producing avermectin or analogues thereof using the recombinant microorganism, and avermectin or analogues thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogues thereof as insecticides. Using the recombinant microorganism of the present invention to produce avermectin or analogues thereof has numerous advantages, for example comprising at least one of the following: good stability, high yield, simple process, environmentally friendly, and greatly saving of production costs.

Abstract: A bacterial strain of Actinoplanes sp. and an application thereof. The bacterial strain is named Actinoplanes sp. HS-16-20, whose preservation number is CGMCC No. 7294. The bacterial strain can generate Fidaxomicin, and Fidaxomicin has an inhibitory effect on various gram positive bacteria pathogens, and in particular, on Clostridium difficile.

Abstract: The present invention relates to a method for preparing highly pure doxorubicin. The method comprises the following steps: (1) chromatographing a prepurified doxorubicin solution by using macroporous resin, pre-washing the chromatographed system by using an acidic low concentration aqueous organic solvent, and performing elution by using an acidic high concentration aqueous organic solvent; (2) performing chromatographic separation on eluted components by using a preparative column, so that a highly pure doxorubicin component can be obtained, and the doxorubicin can, if needed, be separated from the aqueous solution by using conventional concentration and crystallization methods in the prior art. The present invention has the advantages such as simplicity, high yield, low cost, and less environmental pollution. The content of the prepared doxorubicin is greater than 99.5%, the content of each impurity is controlled to be lower than 0.10%, and the USP and EP standards are met.